NEOPHARMA TECHNOLOGIES, LTD.
Investor Relations
Pre-IPO, IPO & Capital Markets Listings
Upon meeting the following criteria, the Company plans to uplist to the New York Stock Exchange:
-
Publicly held Shares: At least 1.1 Million
-
Shareholders: At least 2,200 Shareholders
-
Market Value: A collectively Market Value of at least $100 Million
-
Trading Volume: At least 400 holders of 100 shares or more and an average monthly trading volume of at least 100,000 shares for the most recent six months.
The Company believes it will meet this criterion within 24-36 months of its listing on the OTCQX.
Neopharm Technologies, Ltd. is conducting a Pre-IPO Offering of Convertible Preferred Stock to Qualified Institutional and Retail Investors worldwide. Upon the closing of the Pre-IPO Offering of Convertible Preferred Stock Shares, the Company will list its securities on the OTC Markets' OTCQX (www.OTCMarkets.com).
The Pre-IPO Securities are being offering to Investors under the following exemptions:
-
All California Investors pursuant to California Corporations Code of 1977, Sections 25102(f) & 25102(n);
-
All other U.S. Investors & Canadian Investors under Regulation D Under the Securities Act of 1933; and
-
All Non-U.S. and Non-Canadian Citizens under Regulation S under the Securities Act of 1933.
The Company believes it will complete its listing on the OTCQX in the Summer / Fall of 2025.
To receive a Pre-IPO Investment Prospectus / Offering Memorandum, please call the Company's Investor Relations Team at: Legal@SyndicateAPC.com